Phase 2 N=12 Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans
Healthy
Primary: Plasma Half Life of Labeled Carotenoid — 6.2; 2.3 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=107 Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Cancer of the Breast
Primary: Number of Patients Requiring 2nd Surgery for Close or Positive Margins — 22 participants
Phase 2 N=26 Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Restless Legs Syndrome
Primary: Cmax,ss — 0.633; 1.13; NA; 0.396 ng/mL
Phase 2 N=19 Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
Primary: Safety and Tolerability — 14 participants
Phase 2 N=578 A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
Asthma
Primary: Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo — 4.52; 6.95; 6.00; 0.66 Percentage of Predicted…
Phase 2 N=411 Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Hyperlipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -3.71; 4.54; -14.26; -40.98 percent change — p=<0.001
Phase 2 N=310 A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
Hypercholesterolemia and High Risk for Cardiovascular Events
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -2.71; 0.05; -55.56; -71.32 percent change — p=<0.001
Phase 2 N=82 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Responded to Therapy — 5.6; 11.8; 52.6; 47.1 percentage of participants — p=0.5282
Phase 2 N=688 A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Tested Positive for EGFR Mutations — 8.1 percentage of participants
Phase 2 N=70 Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Progression-free Survival — 1.8; 3.7 months
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Phase 2 N=28 Enhancement of Pressure Healing With Pulsatile Lavage
Spinal Cord Injury
Primary: Pressure Ulcer Geometry — 3.5; 4.9; 2.9; 3.0 cm
Phase 2 N=33 A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months
Phase 2 N=311 Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
Cystic Fibrosis
Primary: Cohort 1: Safety and Tolerability Based on Adverse Events (AEs) — 12; 29; 15; 14 participants
Phase 2 N=12 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
Solid Tumours
Primary: Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) — 6; 1 Participants